Ekso Bionics Holdings, Inc.

Equities

EKSO

US2826443010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-2.34%		-5.30%	-50.00%

Mar. 17	Certain Warrants of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.	CI
Mar. 17	Certain Common Stock of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.	CI

Ekso Bionics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 04, 2024 at 04:15 pm EST

Ekso Bionics Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 18.28 million compared to USD 12.91 million a year ago. Net loss was USD 15.2 million compared to USD 15.08 million a year ago.

Basic loss per share from continuing operations was USD 1.1 compared to USD 1.16 a year ago. Diluted loss per share from continuing operations was USD 1.1 compared to USD 1.16 a year ago.

Latest news about Ekso Bionics Holdings, Inc.

Certain Warrants of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.	Mar. 16	CI
Certain Common Stock of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.	Mar. 16	CI
HC Wainwright Trims Price Target on Ekso Bionics to $9.25 From $10, Keeps Buy Rating	Mar. 05	MT
Transcript : Ekso Bionics Holdings, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
HC Wainwright Adjusts Ekso Bionics Holdings' Price Target to $10 From $9, Keeps Buy Rating	Jan. 22	MT
Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR	Jan. 08	CI
Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023	Jan. 04	CI
Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal	Dec. 12	CI
Transcript : Ekso Bionics Holdings, Inc., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Posts Q3 Revenue $4.6M, vs. Street Est of $4.53M	23-10-26	MT
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Transcript : Ekso Bionics Holdings, Inc., Q2 2023 Earnings Call, Jul 27, 2023	23-07-27
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Reports Q2 Revenue $4.7M, vs. Street Est of $4.35M	23-07-27	MT
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-27	CI
Transcript : Ekso Bionics Holdings, Inc., Q1 2023 Earnings Call, Apr 27, 2023	23-04-27
Ekso Bionics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Posts Q1 Revenue $4.1M, vs. Street Est of $2.8M	23-04-27	MT
Ekso Bionics Holdings, Inc. Announces Resignation of Stanley Stern from the Board, Effective on April 26, 2023	23-04-26	CI
Transcript : Ekso Bionics Holdings, Inc., Q4 2022 Earnings Call, Mar 28, 2023	23-03-28
Ekso Bionics Holdings, Inc Announces Director Changes	22-12-09	CI
Ekso Bionics Buys Parker Hannifin's Human Motion, Control Business for $10 Million; Names Davis CEO	22-12-05	MT
Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.	22-12-04	CI
Transcript : Ekso Bionics Holdings, Inc., Q3 2022 Earnings Call, Nov 03, 2022	22-11-03

Chart Ekso Bionics Holdings, Inc.

Duration

Period

More charts

Company Profile

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Ekso Bionics Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.25 USD

Average target price

9.25 USD

Spread / Average Target

+640.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
EKSO BIONICS HOLDINGS, INC.	-50.00%	22.38M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology